Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Schiff

Showing results (11-20 of 80) with videos related to

Pageof 8
Sort By:
Arthritis Care & Research|June 4, 2014
Future refinement of methotrexate treatment in rheumatoid arthritis: comment on the article by Yazdany et alMichael H Schiff
IEEE Transactions on Bio-Medical Engineering|May 1, 1980
A three-channel three-waveform photostimulator for biophysical research on nervous integrationH Schiff, S Mossino
Seminars in Arthritis and Rheumatism|December 22, 2000
Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritisM H Schiff, A Whelton
Rheumatology International|December 25, 2016
Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritisMichael H Schiff, Peter Sadowski
Biochemistry|August 2, 2023
Mutational Analysis of (+)-Limonene SynthaseWilliam H Schiff, Daniel D Oprian
Urology|July 1, 1985
Rhabdomyolysis and acute renal failure as a complication of urethral surgeryI Leventhal, H Schiff, M Wulfsohn
Urology|March 1, 1982
Radiographic findings in acute segmental pyelonephritisJ R Sotolongo, H Schiff, M A Wulfsohn
Annals of the Rheumatic Diseases|April 15, 2014
Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administrationMichael H Schiff, Jonathan S Jaffe, Bruce Freundlich
Annals of the Rheumatic Diseases|June 26, 2014
Response to: 'is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?' by Fleishman and YaziciMichael H Schiff, Jonathan S Jaffe, Bruce Freundlich
Der Anaesthesist|May 10, 2013
[Anesthesiological considerations for patients with trisomy 21 (Down syndrome)]K Ihringer, N Russ, A Walther, et al.
Pageof 8

Showing results (11-20 of 80) with videos related to

Sort By:
Pageof 8
Arthritis Care & Research|June 4, 2014
Future refinement of methotrexate treatment in rheumatoid arthritis: comment on the article by Yazdany et alMichael H Schiff
IEEE Transactions on Bio-Medical Engineering|May 1, 1980
A three-channel three-waveform photostimulator for biophysical research on nervous integrationH Schiff, S Mossino
Seminars in Arthritis and Rheumatism|December 22, 2000
Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritisM H Schiff, A Whelton
Rheumatology International|December 25, 2016
Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritisMichael H Schiff, Peter Sadowski
Biochemistry|August 2, 2023
Mutational Analysis of (+)-Limonene SynthaseWilliam H Schiff, Daniel D Oprian
Urology|July 1, 1985
Rhabdomyolysis and acute renal failure as a complication of urethral surgeryI Leventhal, H Schiff, M Wulfsohn
Urology|March 1, 1982
Radiographic findings in acute segmental pyelonephritisJ R Sotolongo, H Schiff, M A Wulfsohn
Annals of the Rheumatic Diseases|April 15, 2014
Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administrationMichael H Schiff, Jonathan S Jaffe, Bruce Freundlich
Annals of the Rheumatic Diseases|June 26, 2014
Response to: 'is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?' by Fleishman and YaziciMichael H Schiff, Jonathan S Jaffe, Bruce Freundlich
Der Anaesthesist|May 10, 2013
[Anesthesiological considerations for patients with trisomy 21 (Down syndrome)]K Ihringer, N Russ, A Walther, et al.
Pageof 8